ACE inhibitors and the kidney - A risk-benefit assessment

被引:63
作者
Navis, G [1 ]
Faber, HJ [1 ]
deZeeuw, D [1 ]
deJong, PE [1 ]
机构
[1] UNIV GRONINGEN HOSP, DEPT INTERNAL MED, DIV NEPHROL, GIDS, NL-9713 GZ GRONINGEN, NETHERLANDS
关键词
D O I
10.2165/00002018-199615030-00005
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
ACE inhibitors effectively reduce systemic vascular resistance in patients with hypertension, heart failure or chronic renal disease. This antihypertensive efficacy probably accounts for an important part of their long term renoprotective effects in patients with diabetic and non-diabetic renal disease. The renal mechanisms underlying the renal adverse effects of ACE inhibitors - intrarenal efferent vasodilation with a consequent fall in filtration pressure - are held to be involved in their renoprotective effects as well. The fall in filtration pressure presumably contributes to the antiproteinuric effect as well as to long term renoprotection. The former is suggested by the positive correlation between the fall in filtration fraction and the reduction in proteinuria found during ACE inhibition. The latter is suggested by the correlation between the (slight) reduction in glomerular filtration rate at onset of therapy and a more favourable course of renal function in the long term. Such a fall in filtration rate at the onset of ACE inhibitor treatment is reversible after withdrawal, and can be considered the trade-off for long term renal protection in patients with diabetic and nondiabetic chronic renal disease. In conditions in which glomerular filtration is critically dependent on angiotensin II-mediated efferent vascular tone (such as a post-stenotic kidney, or patients with heart failure and severe depletion of circulating volume), ACE inhibition can induce acute renal failure, which is reversible after withdrawal of the drug. Systemic and renal haemodynamic effects of ACE inhibition, both beneficial and adverse, are potentiated by sodium depletion. Consequently, sodium repletion contributes to the restoration of renal function in patients with ACE inhibitor-induced acute renal failure. On the other hand, co-treatment with diuretics and sodium restriction can improve therapeutic efficacy in patients in whom the therapeutic response of blood pressure or proteinuria is insufficient. Patients at the greatest risk for renal adverse effects (those with heart failure, diabetes mellitus and/or chronic renal failure) also can expect the greatest benefit. Therefore, ACE inhibitors should not be withheld in these patients, but dosages should be carefully titrated, with monitoring of renal function and serum potassium levels.
引用
收藏
页码:200 / 211
页数:12
相关论文
共 109 条
  • [1] THERAPEUTIC ADVANTAGE OF CONVERTING ENZYME-INHIBITORS IN ARRESTING PROGRESSIVE RENAL-DISEASE ASSOCIATED WITH SYSTEMIC HYPERTENSION IN THE RAT
    ANDERSON, S
    RENNKE, HG
    BRENNER, BM
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1986, 77 (06) : 1993 - 2000
  • [2] RENAL RENIN-ANGIOTENSIN SYSTEM IN DIABETES - FUNCTIONAL, IMMUNOHISTOCHEMICAL, AND MOLECULAR BIOLOGICAL CORRELATIONS
    ANDERSON, S
    JUNG, FF
    INGELFINGER, JR
    [J]. AMERICAN JOURNAL OF PHYSIOLOGY, 1993, 265 (04): : F477 - F486
  • [3] SHORT AND LONG-TERM EFFECTS OF ANTIHYPERTENSIVE THERAPY IN THE DIABETIC RAT
    ANDERSON, S
    RENNKE, HG
    GARCIA, DL
    BRENNER, BM
    [J]. KIDNEY INTERNATIONAL, 1989, 36 (04) : 526 - 536
  • [4] APPERLOO AJ, 1994, KIDNEY INT, V45, pS174
  • [5] DIFFERENTIAL-EFFECTS OF ENALAPRIL AND ATENOLOL ON PROTEINURIA AND RENAL HEMODYNAMICS IN NONDIABETIC RENAL-DISEASE
    APPERLOO, AJ
    DEZEEUW, D
    SLUITER, HE
    DEJONG, PE
    [J]. BRITISH MEDICAL JOURNAL, 1991, 303 (6806) : 821 - 824
  • [6] INTERRUPTION OF THE RENIN-ANGIOTENSIN SYSTEM IN HYPERTENSIVE PATIENTS BY CAPTOPRIL INDUCES SUSTAINED REDUCTION IN ALDOSTERONE SECRETION, POTASSIUM RETENTION AND NATRIURESIS
    ATLAS, SA
    CASE, DB
    SEALEY, JE
    LARAGH, JH
    MCKINSTRY, DN
    [J]. HYPERTENSION, 1979, 1 (03) : 274 - 280
  • [7] ANGIOTENSIN-II-STIMULATED PROTEIN-SYNTHESIS IN CULTURED VASCULAR SMOOTH-MUSCLE CELLS
    BERK, BC
    VEKSHTEIN, V
    GORDON, HM
    TSUDA, T
    [J]. HYPERTENSION, 1989, 13 (04) : 305 - 314
  • [8] BENEFICIAL-EFFECTS OF ANGIOTENSIN CONVERTING ENZYME-INHIBITION ON RENAL-FUNCTION IN PATIENTS WITH DIABETIC NEPHROPATHY
    BJORCK, S
    NYBERG, G
    MULEC, H
    GRANERUS, G
    HERLITZ, H
    AURELL, M
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 1986, 293 (6545): : 471 - 474
  • [9] RENAL PROTECTIVE EFFECT OF ENALAPRIL IN DIABETIC NEPHROPATHY
    BJORCK, S
    MULEC, H
    JOHNSEN, SA
    NORDEN, G
    AURELL, M
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 1992, 304 (6823): : 339 - 343
  • [10] BRAVO EL, 1977, KIDNEY INT, V12, P497